GoodRxs introduction of an oral semaglutide access pathway for type 2 diabetes patients reflects broader changes in how GLP-1 therapies are accessed and distributed
1 Thus, their clinical use is expected to grow rapidly not only because of the obesity epidemic but as evidence expands to other indications such as cardiorenal disorders, metabolic liver disease, obstructive sleep apnea, peripheral vascular disease, depression, addiction, and neurodegenerative diseases
It is that retatrutide is the one major GLP-1 with no legitimate supply anywhere, which means there is no safer tier to step down to, no approved product to wait for, no pharmacy version to choose instead
A wealth of information distilled into some great guidelines
Healthcare providers may consider using standardized screening tools such as the PHQ-9 (Patient Health Questionnaire-9) to monitor for depression symptoms during follow-up visits, particularly for patients with pre-existing mental health conditions